BC Week In Review | Nov 2, 2018
Company News

J&J appeals district court decision invalidating Zytiga patent

Johnson & Johnson (NYSE:JNJ) on Oct. 31 filed to appeal a district court decision that will permit generic versions of prostate cancer drug Zytiga abiraterone acetate to launch after Oct. 31, according to company spokesperson...
BC Week In Review | Feb 16, 2018
Clinical News

FDA expands label for Zytiga

Johnson & Johnson (NYSE:JNJ) said FDA approved a new indication for Zytiga abiraterone acetate (CB7630) in combination with prednisone to treat metastatic high-risk castration-sensitive prostate cancer (CSPC). The approval is based on data from a...
BC Week In Review | Jan 19, 2018
Company News

PTAB invalidates Zytiga patent

In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board invalidated all 20 claims of U.S. Patent No. 8,822,438 covering prostate cancer drug Zytiga abiraterone acetate from Johnson & Johnson (NYSE:JNJ)....
BC Extra | Jan 18, 2018
Company News

PTAB invalidates Zytiga patent

In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board invalidated all 20 claims of U.S. Patent No. 8,822,438 covering prostate cancer drug Zytiga abiraterone acetate from Johnson & Johnson (NYSE:JNJ)....
BC Week In Review | Dec 1, 2017
Clinical News

CHMP recommends label expansion for J&J prostate cancer drug Zytiga

EMA's CHMP recommended approval of a label expansion for Zytiga abiraterone acetate (CB7630) from Johnson & Johnson (NYSE:JNJ) to include treatment of newly diagnosed, high-risk, hormone-sensitive metastatic prostate cancer in adult men in combination with...
BC Week In Review | Jun 16, 2017
Clinical News

J&J's Zytiga meets in Phase II/III STAMPEDE trial for hormone-naïve prostate cancer

Johnson & Johnson (NYSE:JNJ) reported data from the Phase II/III STAMPEDE trial in 1,917 patients with high-risk, locally advanced or metastatic hormone-naïve prostate cancer showing that Zytiga abiraterone acetate (CB7630) plus androgen deprivation therapy met...
BC Week In Review | Jun 16, 2017
Clinical News

J&J's Zytiga meets in Phase III LATITUDE trial for hormone-naïve prostate cancer

Johnson & Johnson (NYSE:JNJ) reported data from the Phase III LATITUDE trial in 1,199 patients with newly diagnosed, high-risk metastatic hormone-naïve prostate cancer showing that Zytiga abiraterone acetate (CB7630) plus androgen deprivation therapy met the...
BC Week In Review | Mar 28, 2016
Company News

J&J sales and marketing update

The U.K.’s NICE issued final guidance recommending Zytiga abiraterone from Johnson & Johnson to treat metastatic castration-resistant prostate cancer (CRPC) in patients whose first treatment has failed and for whom chemotherapy is not yet clinically...
BC Week In Review | Dec 14, 2015
Company News

BTG, J&J sales and marketing update

The U.K.’s NICE issued a second final appraisal determination (FAD) recommending against the use of Zytiga abiraterone from Johnson & Johnson to treat metastatic castration-resistant prostate cancer (CRPC) in patients whose first treatment has failed...
BC Week In Review | Sep 1, 2014
Clinical News

Zytiga regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending against the use of Zytiga abiraterone from Johnson & Johnson in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (CRPC) -- 1 of its approved indications...
Items per page:
1 - 10 of 151
BC Week In Review | Nov 2, 2018
Company News

J&J appeals district court decision invalidating Zytiga patent

Johnson & Johnson (NYSE:JNJ) on Oct. 31 filed to appeal a district court decision that will permit generic versions of prostate cancer drug Zytiga abiraterone acetate to launch after Oct. 31, according to company spokesperson...
BC Week In Review | Feb 16, 2018
Clinical News

FDA expands label for Zytiga

Johnson & Johnson (NYSE:JNJ) said FDA approved a new indication for Zytiga abiraterone acetate (CB7630) in combination with prednisone to treat metastatic high-risk castration-sensitive prostate cancer (CSPC). The approval is based on data from a...
BC Week In Review | Jan 19, 2018
Company News

PTAB invalidates Zytiga patent

In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board invalidated all 20 claims of U.S. Patent No. 8,822,438 covering prostate cancer drug Zytiga abiraterone acetate from Johnson & Johnson (NYSE:JNJ)....
BC Extra | Jan 18, 2018
Company News

PTAB invalidates Zytiga patent

In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board invalidated all 20 claims of U.S. Patent No. 8,822,438 covering prostate cancer drug Zytiga abiraterone acetate from Johnson & Johnson (NYSE:JNJ)....
BC Week In Review | Dec 1, 2017
Clinical News

CHMP recommends label expansion for J&J prostate cancer drug Zytiga

EMA's CHMP recommended approval of a label expansion for Zytiga abiraterone acetate (CB7630) from Johnson & Johnson (NYSE:JNJ) to include treatment of newly diagnosed, high-risk, hormone-sensitive metastatic prostate cancer in adult men in combination with...
BC Week In Review | Jun 16, 2017
Clinical News

J&J's Zytiga meets in Phase II/III STAMPEDE trial for hormone-naïve prostate cancer

Johnson & Johnson (NYSE:JNJ) reported data from the Phase II/III STAMPEDE trial in 1,917 patients with high-risk, locally advanced or metastatic hormone-naïve prostate cancer showing that Zytiga abiraterone acetate (CB7630) plus androgen deprivation therapy met...
BC Week In Review | Jun 16, 2017
Clinical News

J&J's Zytiga meets in Phase III LATITUDE trial for hormone-naïve prostate cancer

Johnson & Johnson (NYSE:JNJ) reported data from the Phase III LATITUDE trial in 1,199 patients with newly diagnosed, high-risk metastatic hormone-naïve prostate cancer showing that Zytiga abiraterone acetate (CB7630) plus androgen deprivation therapy met the...
BC Week In Review | Mar 28, 2016
Company News

J&J sales and marketing update

The U.K.’s NICE issued final guidance recommending Zytiga abiraterone from Johnson & Johnson to treat metastatic castration-resistant prostate cancer (CRPC) in patients whose first treatment has failed and for whom chemotherapy is not yet clinically...
BC Week In Review | Dec 14, 2015
Company News

BTG, J&J sales and marketing update

The U.K.’s NICE issued a second final appraisal determination (FAD) recommending against the use of Zytiga abiraterone from Johnson & Johnson to treat metastatic castration-resistant prostate cancer (CRPC) in patients whose first treatment has failed...
BC Week In Review | Sep 1, 2014
Clinical News

Zytiga regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending against the use of Zytiga abiraterone from Johnson & Johnson in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (CRPC) -- 1 of its approved indications...
Items per page:
1 - 10 of 151